4//SEC Filing
Solomon Jonathan Eitan 4
Accession 0001213900-23-095417
CIK 0001739174other
Filed
Dec 12, 7:00 PM ET
Accepted
Dec 13, 4:42 PM ET
Size
18.6 KB
Accession
0001213900-23-095417
Insider Transaction Report
Form 4
BiomX Inc.PHGE
Solomon Jonathan Eitan
DirectorChief Executive Officer
Transactions
- Disposition to Issuer
Common Stock Options - Right to Buy
2023-12-11−144,000→ 0 totalExercise: $6.21Exp: 2030-03-25→ Common Stock (144,000 underlying) - Award
Common Stock Options - Right to Buy
2023-12-11+146,429→ 146,429 totalExercise: $0.27Exp: 2032-03-29→ Common Stock (146,429 underlying) - Award
Common Stock Options - Right to Buy
2023-12-11+37,895→ 37,895 totalExercise: $0.27Exp: 2030-03-25→ Common Stock (37,895 underlying) - Disposition to Issuer
Common Stock Options - Right to Buy
2023-12-11−152,000→ 0 totalExercise: $7.02Exp: 2031-03-30→ Common Stock (152,000 underlying) - Award
Common Stock Options - Right to Buy
2023-12-11+40,000→ 40,000 totalExercise: $0.27Exp: 2031-03-30→ Common Stock (40,000 underlying) - Disposition to Issuer
Common Stock Options - Right to Buy
2023-12-11−205,000→ 0 totalExercise: $1.41Exp: 2032-03-29→ Common Stock (205,000 underlying)
Footnotes (6)
- [F1]On December 11, 2023, the Issuer canceled, pursuant to the Issuer's option exchange program, an option for 144,000 shares of the Issuer's common stock granted to the Reporting Person on March 25, 2020. In exchange, the Reporting Person received a replacement option, for 37,895 shares, having an exercise price of $0.2749 per share.
- [F2]The cancelled option provided for vesting over four years, with 25% of the shares subject to the option vested on March 25, 2021, and the remainder vested in 12 equal quarterly installments over three years. The replacement option vests according to the same vesting schedule applicable to the cancelled option; provided, however, that the replacement option may not be exercised prior to December 11, 2024.
- [F3]On December 11, 2023, the Issuer canceled, pursuant to the Issuer's option exchange program, an option for 152,000 shares of the Issuer's common stock granted to the Reporting Person on March 30, 2021. In exchange, the Reporting Person received a replacement option, for 40,000 shares, having an exercise price of $0.2749 per share.
- [F4]The cancelled option provided for vesting over four years, with 25% of the shares subject to the option vested on March 30, 2022, and the remainder vested in 12 equal quarterly installments over three years. The replacement option vests according to the same vesting schedule applicable to the cancelled option; provided, however, that the replacement option may not be exercised prior to December 11, 2024.
- [F5]On December 11, 2023, the Issuer canceled, pursuant to the Issuer's option exchange program, an option for 205,000 shares of the Issuer's common stock granted to the Reporting Person on March 29, 2022. In exchange, the Reporting Person received a replacement option, for 146,429 shares, having an exercise price of $0.2749 per share.
- [F6]The cancelled option provided for vesting over four years, with 25% of the shares subject to the option vested on March 29, 2023, and the remainder vested in 12 equal quarterly installments over three years. The replacement option vests according to the same vesting schedule applicable to the cancelled option; provided, however, that the replacement option may not be exercised prior to December 11, 2024.
Documents
Issuer
BiomX Inc.
CIK 0001739174
Entity typeother
Related Parties
1- filerCIK 0001792322
Filing Metadata
- Form type
- 4
- Filed
- Dec 12, 7:00 PM ET
- Accepted
- Dec 13, 4:42 PM ET
- Size
- 18.6 KB